Ezetimibe cost-effective option in statin intolerance

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer's Disease

By Kirbach Stephanie  

Clinical Drug Investigation, Vol. 28, Iss. 5, 2008-01 ,pp. : 291-303

Adis International

Access to resources Recommend Favorite

Effectiveness and Safety of Ezetimibe Added to Statin Therapy in Patients with Primary Dyslipidaemia not Achieving the LDL-C Treatment Goal on Statin Monotherapy

By González Carlos A.   Rubio-Guerra Alberto F.   Pavía Abel   Redding Francisco J.   Cervantes José L.   Zacarías José L.   Yza Rubén   Carranza Jaime   Fernández Pedro   Morales Enrique   Robles Francisco J.   Leyva José L.   Rodríguez Leticia  

Clinical Drug Investigation, Vol. 27, Iss. 5, 2007-01 ,pp. : 333-337

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model

By Kreck Simon   Klaus Jochen  

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 311-328

Adis International

Access to resources Recommend Favorite

Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study

By Reckless John   Davies Glenn   Tunceli Kaan   Hu X. Henry   Brudi Philippe  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 726-734

Blackwell Publishing

Access to resources Recommend Favorite